Uni-Bio Science Forms Strategic Alliance to Advance Growth Factor Combination Therapies in Regenerative Medicine
核心洞察
Uni-Bio Science Group signed a tripartite strategic cooperation agreement with Wenzhou Medical University's National Engineering Research Center and Ouhai District Government to develop combined EGF (搜索)/FGF (搜索) therapies.
The collaboration will establish a joint innovation laboratory focusing on synergistic mechanisms of epidermal growth factor and fibroblast growth factor for treating metabolic disorders, respiratory diseases, and tissue repair.
The partnership targets development of novel compound formulations for conditions including non-alcoholic steatohepatitis (NASH), asthma, and bone tissue repair, addressing significant unmet clinical needs.
Uni-Bio Science Group Limited announced the signing of a tripartite strategic cooperation agreement with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University (WMU NERC) and the People's Government of Ouhai District, Wenzhou. The collaboration establishes a "government-university-enterprise" model focused on growth factor innovation in regenerative medicine, marking a significant milestone in the company's strategic execution.
The partnership will create an end-to-end innovation system spanning basic research, clinical translation, and industrial application. The parties plan to co-establish the "Uni-Bio – WMU Joint Innovation Laboratory for Translational Medicine" to advance combined epidermal growth factor (EGF (搜索)) and fibroblast growth factor (FGF (搜索)) therapies.
Targeting Synergistic Growth Factor Mechanisms
The planned joint laboratory will conduct in-depth research into the synergistic mechanisms of EGF (搜索) and FGF (搜索) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair. The collaboration aims to develop novel compound formulations and drug delivery systems targeting endocrine diseases such as non-alcoholic steatohepatitis (NASH), respiratory diseases including asthma, and bone tissue repair applications.
According to the announcement, these diseases affect a large global patient population, yet there remains significant unmet clinical need for innovative therapies. The partnership is expected to address treatment gaps in multiple specific indications, unlocking clinical and commercial value in the broad chronic disease market.
Complementary Expertise and Capabilities
Uni-Bio brings deep expertise in the EGF (搜索) field, with flagship products GeneTime® and GeneSoft® achieving large-scale production and nationwide commercial coverage. The WMU NERC, under the leadership of Chinese Academy of Engineering Academician Li Xiaokun, has been a global pioneer in FGF (搜索) drug research and development, successfully translating several Class I New Drugs including Recombinant Human Basic Fibroblast Growth Factor.
The Center has accumulated substantial clinical data and authoritative expert consensus in trauma and metabolic diseases. Through ongoing research, Academician Li Xiaokun's team has achieved internationally leading breakthroughs in key technologies, including long-acting modification, targeted delivery, and aerosol inhalation.
Comprehensive Research Infrastructure
The WMU NERC operates as an independent legal entity established by Wenzhou Medical University based on the national-level platform. It undertakes downstream functions including engineering technology research and development, transformation of scientific achievements, and technical services. In collaboration with the National Key Laboratory for Macromolecular Drugs and Large-Scale Preparation, the Center has built a next-generation growth factor drug pipeline targeting multiple systems including metabolism and dermatology.
The Center serves as the research engine of the China Gene Valley and continuously promotes the incubation and translation of several original new drug candidates, including a long-acting FGF21 (搜索) variant.
Strategic Implementation Framework
The collaboration will initiate research on combined EGF (搜索)/FGF (搜索) therapies for key therapeutic areas including burns, dermatology, and ophthalmology. The goal is to unlock powerful therapeutic synergies, develop superior combination products and advanced delivery systems, set new treatment benchmarks, and establish leadership in this multi-billion yuan sector.
For Uni-Bio, the tripartite cooperation delivers threefold empowerment: direct access to the National Engineering Research Center's source innovation and core technologies on the R&D front; collaboration with Wenzhou Medical University's affiliated hospital network to accelerate clinical validation and indication expansion on the clinical front; and leveraging advanced manufacturing capabilities and regional policy benefits of the China Gene Valley for efficient project implementation and market access on the commercialization front.
Regional Innovation Ecosystem
The People's Government of Ouhai District, Wenzhou serves as a key facilitator and supporter of the strategic cooperation, committed to building a first-class biomedical industry ecosystem. The core platform, "China Gene Valley," provides comprehensive spatial support and specialized policy assistance for cooperative projects across all stages from R&D and pilot-scale testing to industrialization.
Through specialized industrial policies, "full-cycle escort" services, and clinical resource coordination, Ouhai District empowers the implementation and growth of innovation projects, serving as a vital driver for regional biomedical industry innovation and development.
The strategic partnership represents a crucial step in Uni-Bio's pursuit of its vision "To Be the Global Leader in Regenerative Medicine, Redefining How Science Restores and Extends Human Life." The company plans to continue deepening collaborations with national scientific institutions and local governments to drive translation of cutting-edge research into clinical and market value.